ACTU Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -9.12%, SMA50 -26.71%, SMA200 -43.56%). The stock’s 14-day RSI is 34.21 (weak momentum), while the ATR of 0.38 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -67.06% below its high and over 6.33% above its low. Average 10-day trading volume of 222.92 thousand shares is below the 3-month average of 259.44 thousand, indicating normal recent market interest.

Actuate Therapeutics Inc has 23.93 million shares outstanding. The public float is 8.57 million shares, elevated short interest at 7.21% of float. This equals 754.75 thousand shares. The short ratio is 1.72 days. Institutional investors hold 68.34% of the float. Insiders own 14.84%. THOMSON TODD S holds 904.80 thousand shares, Bios Equity COF, LP has 71.43 thousand shares and Kreis Leslie W. has 71.43 thousand shares.

Actuate Therapeutics Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.61. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of 29.0% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $6.00. The high target offers 1961.86% upside. The low target suggests 518.56% downside. The mean target is $16.38. This offers 1588.66% upside. Actuate Therapeutics Inc earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by 4.35%. The prior quarter beat by -25.0%. Over the last six quarters, Apple has recorded several small beats. These include 13.79% in March 13, 2025.

The stock is currently mid-range between its 52-week high and low $0.91 and $9.22. With a market capitalization of about $23.33 million, Actuate Therapeutics Inc is classified as a micro-cap and shows lower-than-market volatility (beta ~0.78). Key stats such as the average daily volume over the past year has been around 260.28 thousand shares, volume is running light vs its 52-week average. Headquartered in Fort Worth, TX, Actuate Therapeutics Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel Schmitt, the company employs approximately 12 people and listed since August 13, 2024. Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers.

Our AI price prediction model suggests that Actuate Therapeutics Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -20.61%, with price expected at $0.77 by August 26, 2026, within a range of $0.58 to $0.96 3-Month Outlook: Projected fall of -54.63%, reaching $0.44 by November 10, 2026, with a range of $0.30 to $0.60. 1-Year Outlook: Projected loss of -93.81%, with price at $0.06 by August 12, 2027, within a range of $0.00 to $0.14.

Actuate Therapeutics Inc (NASDAQ:ACTU) shares are flat -9.15% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Actuate Therapeutics Inc trading at a premium to the broader market with a P/E of -0.99. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.78, suggesting 1630.08% upside. Our AI forecast model points to short-term weakness (-20.61% over two weeks), a medium-term fall (-54.63% over three months), and a longer-term loss (-93.81% over one year), with expected trading ranges indicating moderate volatility.

Actuate Therapeutics Inc trades at a P/E ratio of -0.99, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.1 trading at moderately above to book value. The P/FCF stands at -1.2, also below market averages.